HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.

AuthorsN von Bubnoff, S H P Gorantla, R K Kancha, F Lordick, C Peschel, J Duyster
JournalLeukemia (Leukemia) Vol. 19 Issue 9 Pg. 1670-1 (Sep 2005) ISSN: 0887-6924 [Print] England
PMID16015383 (Publication Type: Letter)
Chemical References
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-kit
  • nilotinib
Topics
  • Amino Acid Substitution
  • Animals
  • Apoptosis (drug effects)
  • Benzamides
  • Cell Line
  • Cell Proliferation (drug effects)
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (pharmacology)
  • Humans
  • Imatinib Mesylate
  • Mastocytosis, Systemic (genetics)
  • Mice
  • Mutation
  • Piperazines (pharmacology)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Proto-Oncogene Proteins c-kit (drug effects, genetics)
  • Pyrimidines (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: